NCT00434824View on ClinicalTrials.gov

Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)

PHASE2CompletedINTERVENTIONAL
Enrollment

322

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
HypogonadismAndrogens
Interventions
DRUG

Oral testosterone undecanoate (Andriol)

treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses

DRUG

Placebo

treatment for 12 months with placebo in divided doses

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00434824 - Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203) | Biotech Hunter | Biotech Hunter